The treatment of CAT in the real-world setting: CAT treatment algorithm
During the ICTHIC webinar “Clinical insights in CAT to include COVID‐19“, Prof. Florian Langer gave a...
Therapy
Multiple myeloma-associated VTE risk prediction. A talk report from the 10th ICTHIC
During the 10th ICTHIC, prof Kristen Sanfilippo (Assistant Professor at the Washington University School of Medicine in...
VTE in Palliative Care Patients: What do we know? A talk report from the 10th ICTHC
During the 10th ICTHIC, Professor Simon Noble (Cardiff University, UK) talked about the management of VTE in patients...
Venous thromboembolism risk and immune checkpoint inhibitors: what the literature says.
Patients with cancer have an increased risk of venous and arterial thromboembolism (VTE/ATE) . Several factors have...
Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia and preliminary data from the MATTER study: A talk report from the 10th ICTHIC conference
During the 10th ICTHIC, Dr. Avi Leader (hematologist at Rabin Medical Center in Petah Tikva, Israel) talked about...
CAT treatment in challenging patient categories: what the literature says
Patients with cancer are at high risk of venous thromboembolism (VTE). Fortunately, patient survival, diagnostic tools...
Incidental VTE: to treat or not to treat? – A debate from the 10th ICTHIC
During the 10th ICTHIC, Prof. Marcello di Nisio (University of Chieti, Italy) and Prof. Marc Carrier (Ottawa Hospital...
Differences in thromboprophylaxis between hospitalized patients with solid or hematological malignancies: A talk with Prof. Páramo
José Antonio Páramo is a Professor of Hematology at the University Clinic of Navarra, University of Navarra,...
Risk assessment models for venous thromboembolism in ambulatory patients with cancer: A talk with Prof. Gerotziafas
Prof Gerotziafas is a specialist in thrombosis and hemostasis with a particular interest in cancer-associated...
Venous and arterial thromboembolism in patients with cancer treated with immune checkpoint inhibitor therapy
Patients with cancer are at an increased risk of venous and arterial thromboembolism (VTE/ATE) . A number of factors...